PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES

Impaired B-cell immunological tolerance plays a central role in the pathogenesis of immuno-inflammatory rheumatic diseases (IIRD). B-cells link innate and acquired immunity: they express Toll-like receptors that respond to danger signals; act as antigen-presenting cells; induce an antigen-specific immune response; determine the development of immunological memory; and synthesize a wide range of cytokines that regulate (stimulate or suppress) an immune response and inflammation. In IIRD, there are metabolic and B-cellular signaling disturbances that lead to defects in B-regulatory, T-regulatory, follicular T-helper, and dendritic cells. B-cells synthesize organ-nonspecific and organspecific autoantibodies that are biomarkers  for autoimmune diseases and play an important role in their immunopathogenesis. Anti-B-cell therapy that causes B-cell depletion in blood and target organs is effective in a wide range of IIRD. Its efficiency is determined by various mechanisms, such as suppression of pathogenic autoantibody synthesis; modulation of the function of B-cells (antigen presentation, cytokine synthesis, and costimulation), T-lymphocytes and dendritic cells. Further study of a strategy for targeted anti-B-cell therapy, mechanisms of action, and new targets is important for the progress of modern rheumatology to improve the treatment strategy of IIRD.

immuno-inflammatory rheumatis diseases, B-cells, rituximab, belimumab, biosimilars, Acellbia

1. Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2:594-600. doi: 10.1016/j.jaip.2014.06.003

2. Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.

3. Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176

4. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized therapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 2015;70(2):169-82 (In Russ.).

5. Kobelt G, Kasteng F. Access to Innovative Treatments in Rheumatoid Arthritis in Europe. 2009. Available at: http://www.comparatorreports.se/Access to MS treatments - October 2009.pdf

6. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med. 2015;278:369-95. doi: 10.1111/joim.12395

7. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956

8. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703

9. Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279

10. Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059

11. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555

12. Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.

13. Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419

14. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.). doi: 10.14412/1995-4484-2017-409-419

15. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041

16. Dö rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974-82. doi: 10.1136/annrheumdis-2016-209166

17. Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170

18. Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165-74. doi: 10.1136/annrheumdis-2017-211937

19. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-33. doi: 10.1172/JCI78088

20. Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279

21. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484

22. Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900

23. Theofilopoulos AN, Kono DH, Baccala R. The Multiple Pathways to Autoimmunity. Nat Immunol. 2017;18:716-24. doi: 10.1038/ni.3731

24. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116

25. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360

26. Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203-10. doi: 10.1172/JCI78083

27. Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015

28. Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.). doi: 10.14412/1995-4484-2016-628-640

29. Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771

30. Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.

31. Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018.

32. Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol. 2019;15(5):303-15. doi: 10.1038/s41584-019-0211-0

33. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003

34. Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155

35. Yoo DH, Suh CH, Shim SC, et al. A multicentre randomized controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566-70. doi: 10.1136/annrheumdis-2016-209540

36. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194-202. doi: 10.1172/JCI78084

37. Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934-43. doi: 10.1080/19420862.2018.1487912

38. Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480

39. Jennewein MF, Alter G. The Immunoregulatory Roles of Antibody Glycosylation. Trends Immunol. 2017;38(5):358-72. doi: 10.1016/j.it.2017.02.004

40. Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003

41. Cohen SB, Burgos-Vargas R, Emery P, et al. An extension study of PF-05280586, a potential Rituximab biosimilar, versus Rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23586

42. Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338

43. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-z

44. Forestier A, Guerrier T, Jouvray M, et al. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmun Rev. 2018;17(3):244-55. doi: 10.1016/j.autrev.2017.10.015

45. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152

46. Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjö gren syndrome. Nat Rev Rheumatol. 2018;14(3):133-45. doi: 10.1038/nrrheum.2018.1

47. Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55

48. Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.). doi: 10.14412/1995-4484-2017-201-210

49. Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.). doi: 10.14412/1995-4484-2016-510-519

50. McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103

51. Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563

52. Von Borstel A, Sanders JS, Rutgers A, et al. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2018 Apr;17(4):413-21. doi: 10.1016/j.autrev.2017.12.002

53. Dö rner T, Lipsky PE. Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. Nat Rev Rheumatol. 2016 Nov;12(11):645-57. doi: 10.1038/nrrheum.2016.158

54. Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18

55. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007

56. Nasonov EL, Mazurov VI, Zonova EV, et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: Results of Phase III (ALTERRA) clinical trial. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):351-9 (In Russ.). doi: 10.14412/1995-4484-2017-351-359

57. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427

58. Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.

59. Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 Dec;43:39-45. doi: 10.1016/j.coi.2016.09.003

60. Bredemeier M, de Oliveira FK, Rocha CM. Low-versus Highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. doi: 10.1002/acr.22116

61. Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498

62. Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004

63. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi: 10.1136/ard.2010.144998

64. Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? Front Immunol. 2017;4(8):1245. doi: 10.3389/fimmu.2017.01245

65. Hofmann K, Clauder AK, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018 Apr 23;9:835. doi: 10.3389/fimmu.2018.00835

66. Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14

67. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650

68. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi: 10.1002/art.21778

69. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025

70. Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: focus on rituximab]. Moscow: IMAPRESS; 2012. P. 119-52 (In Russ.).

71. Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.

72. Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571

73. Nasonov EL. Prospects for anti-B-cell therapy in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):539-48 (In Russ.). doi: 10.14412/1995-4484-2018-539-548

74. Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.

75. Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251

76. Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.

77. Sakkas LI, Daoussis D, Mavropoulos A, et al. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum. 2019;48(6):1133-41. doi: 10.1016/j.semarthrit.2018.10.007

78. Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939

79. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis. 2010;69:1629-35. doi: 10.1136/ard.2009.119933

80. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199

81. Taha R, El-Haddad H, Almuallim A, et al. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schö nlein purpura, ankylosing spondylitis, and Raynaud's phenomenon. Open Access Rheumatol. 2017 Dec 15;9:201-14. doi: 10.2147/OARRR.S149373

82. Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.x

83. Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.

84. Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102

85. Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12. doi: 10.1007/s13317-017-0100-y

86. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703

87. Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505

88. Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176

89. Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.

90. Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519

91. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956

92. Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191

93. Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419

94. Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009

95. Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059

96. Masoud S, McAdoo SP, Bedi R, et al. Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford). 2018 Mar 19. doi: 10.1093/rheumatology/key042

97. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041

98. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150

99. Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170

100. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365-73. doi: 10.1038/nrrheum.2014.33

101. Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279

102. Sanz I. Connective tissue diseases: targeting B cells in SLE: good news at last! Nat Rev Rheumatol. 2011;7(5):255-6. doi: 10.1038/nrrheum.2011.48

103. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133

104. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484

105. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116

106. Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-PRESS; 2013. 552 p..

107. Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015

108. Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166

109. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360

110. Kusevich DA, Avdeeva AS. The efficacy and safety of rituximab in rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):420-8 (In Russ.). doi: 10.14412/1995-4484-2017-420-428

111. Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771

112. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0

113. Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.

114. Cohen MD, Keystone E. Rituximab for rheumatoid arthritis. Rheumatol Ther. 2015;2(2):99-111. doi: 10.1007/s40744-015-0016-9

115. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003

116. Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.

117. Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155

118. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715

119. Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560

120. Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480

121. Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003

122. Nasonov EL, editor. Revmatologiya. Rossiyskie klinicheskie rekomendatsii [Rheumatology. Russian Clinical Recommendations]. Moscow: GEOTAR-Media; 2017. 456 p..

123. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-z

124. Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338

125. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80. doi: 10.1136/ard.2010.148759

126. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152

127. Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55

128. Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72(3):329-36. doi: 10.1136/annrheumdis-2011-201117

129. McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103

130. Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563

131. Avdeeva AS, Kusevich DA. The role of laboratory biomarkers in predicting the efficiency of rituximab therapy for rheumatoid arthritis: New evidence. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):295-303 (In Russ.). doi: 10.14412/1995-4484-2017-295-303

132. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007

133. Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18

134. Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.

135. Cuppen BV, Welsing PM, Sprengers JJ, et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology (Oxford). 2016;55(5):826-39. doi: 10.1093/rheumatology/kev421

136. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427

137. Scherer HU, Huizinga TWJ, Krö nke G, et al. The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(3):157-69. doi: 10.1038/nrrheum.201

138. Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498

139. Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004

140. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650

141. Razawy W, van Driel M, Lubberts E. The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018;48(2):220-9. doi: 10.1002/eji.201646787

142. Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14

143. Pfeifle R, Rothe T, Ipseiz N, et al. Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. 2017;18:104-13. doi: 10.1038/ni.3579

144. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025

145. Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571

146. Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.

147. Van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The antiCD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum. 2011;63(6):1507-16. doi: 10.1002/art.30314

148. Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251

149. Alunno A, Carubbi F, Bistoni O, et al. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjö gren's syndrome: a pilot study. Clin Exp Immunol. 2016;184(3):284-92. doi: 10.1111/cei.12771

150. Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939

151. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199

152. Molendijk M, Hazes JM, Lubberts E. From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis? RMD Open. 2018;4(1):e000256. doi: 10.1136/rmdopen-2016-000256

153. Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.x

154. Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102

155. Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505

156. Nasonov EL. Problems of rheumatoid arthritis immunopathology: Evolution of the disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(3):277-94 (In Russ.). doi: 10.14412/1995-4484-2017-277-294

157. Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176

158. Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519

159. Gerlag DM, Safy M, Maijer KI, et al. A single infusion of rituximab delays the onset of arthritis in subjects at high risk of developing RA [abstract]. Arthritis Rheum. 2016;68 Suppl 10.

160. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956

161. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715

162. Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009

163. Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059

164. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150

165. Food and Drug Administration [webpage on the Internet]. Questions and Answers on Rituximab (added 12/19/2006). Available from: https://wayback.archiveit.org/7993/20170722191606/; https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109107.htm. Accessed August 9, 2017.

166. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041

167. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133

168. Lally L, Spiera R. B-cell-targeted therapy in systemic vasculitis. Curr Opin Rheumatol. 2016;28(1):15-20. doi: 10.1097/BOR.0000000000000235

169. Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279

170. McClure M, Gopaluni S, Jayne D, Jones R. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol. 2018;14(10):580-91. doi: 10.1038/s41584-018-0065-x

171. Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166

172. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484

173. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0

174. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-32. doi: 10.1056/NEJMoa0909905

175. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360

176. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417-27. doi: 10.1056/NEJMoa1213277

177. Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.

178. Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771

179. Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560

180. Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in ANCA-associated vasculitis. Arthritis Rheum. 2014;66(11):3151-9. doi: 10.1002/art.38788

181. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003

182. Geetha D, Specks U, Stone JH, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol. 2015;26(4):976-85. doi: 10.1681/ASN.2014010046

183. Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003

184. Fussner LA, Hummel AM, Schroeder DR, et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheum. 2016;68(7):1700-10. doi: 10.1002/art.39637

185. Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338

186. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-20. doi: 10.1056/NEJMoa0909169

187. Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55

188. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178-82. doi: 10.1136/annrheumdis-2014-206404

189. Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563

190. Walsh M, Flossmann O, Berden A, et al; European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542-8. doi: 10.1002/art.33361

191. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007

192. Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum. 2012;64:3760-9. doi: 10.1002/art.34583

193. Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.

194. Bunch DO, McGregor JG, Khandoobhai NB, et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013;8:382-91. doi: 10.2215/CJN.03950412

195. Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498

196. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771-80. doi: 10.1056/NEJMoa1404231

197. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650

198. Terrier B, Pagnoux C, Perrodeau E, et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann Rheum Dis. 2018;77(8):1150-6. doi: 10.1136/annrheumdis-2017-21

199. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025

200. Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti- neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017 Mar 7. doi: 10.1186/s13063-017-1857-z

201. Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.

202. Charles P, Terrier B, Perrodeau E, et al; French Vasculitis Study Group. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143-9. doi: 10.1136/annrheumdis-2017-212878

203. Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939

204. Alberici F, Smith RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford). 2015;54(7):1153-60. doi: 10.1093/rheumatology/keu452

205. Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.x

206. Recillas-Gispert C, Serna-Ojeda JC, Flores-Suarez LF. Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). Graefes Arch Clin Exp Ophthalmol. 2015;253(12):2279-84. doi: 10.1007/s00417-015-3198-5

207. Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505

208. Henderson SR, Copley SJ, Pusey CD, et al. Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore). 2014;93(27):e229. doi: 10.1097/MD.0000000000000229

209. Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519

210. Umezawa N, Kohsaka H, Nanki T, et al. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIg. Mod Rheumatol. 2014;24(4):685-7. doi: 10.3109/14397595.2013.874734

211. Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009

212. Thiel J, Hassler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther. 2013;15(5):R133. doi: 10.1186/ar4313

213. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150

214. Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (ChurgStrauss) Ann Rheum Dis. 2016;75(2):396-401. doi: 10.1136/annrheumdis-2014-206095

215. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133

216. Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019 Jun 5;5(1):e000905. doi: 10.1136/rmdopen-2019-000905

217. Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166

218. Wendt M, Gunnarsson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients. Scand J Rheumatol. 2012;41(2):116-9. doi: 10.3109/03009742.2011.620573

219. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0

220. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum. 2012;64(11):3770-8. doi: 10.1002/art.34584

221. Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.

222. Pendergraft WF, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-Cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol. 2014;9(4):736-44. doi: 10.2215/CJN.07340713

223. Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560

224. Charles P, Neel A, Tieulie N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53(3):532-9. doi: 10.1093/rheumatology/ket381

225. Nagafuchi H, Atsumi T, Hatta K, et al. Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis. Mod Rheumatol. 2015;25(4):603-8. doi: 10.3109/14397595.2014.981945

226. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1394-400. doi: 10.2215/CJN.08821209

227. Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol. 2012;39(1):125-30. doi: 10.3899/jrheum.110143

228. Calich AL, Puechal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's): results of a single-center cohort study on 66 patients. J Autoimmun. 2014;50:135-41. doi: 10.1016/j.jaut.2014.03.002

229. Cortazar FB, Muhsin SA, Pendergraft WF 3rd, et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2017;3(2):394-402. doi: 10.1016/j.ekir.2017.11.004

230. Cortazar FB, Pendergraft WF 3rd, Wenger J, et al. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2017;69(5):1045-53. doi: 10.1002/art.40032

231. Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):495-506 (In Russ.). doi: 10.14412/1995-4484-2014-495-506

232. Beketova TV, Aleksandrova EN, Novoselova TM, et al. Russian experience with using monoclonal antibodies to B lymphocytes (rituximab) in systemic vasculitides associated with neutrophil cytoplasmic antibodies (preliminary results of the Russian Register NORMA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):147-58 (In Russ.). doi: 10.14412/1995-4484-2014-147-158

233. Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch-Schö nlein purpura. J Pediatr. 2009;155(1):136-9. doi: 10.1016/j.jpeds.2008.12.049

234. Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch-Schö nlein purpura: case report. Nephrol Dial Transplant. 2011;26(6):2044-6. doi: 10.1093/ndt/gfr137

235. Maritati F, Fenoglio R, Pillebout E, et al. Brief report: Rituximab for the treatment of adult-onset IgA vasculitis (HenochSchö nlein). Arthritis Rheum. 2018;70(1):109-14. doi: 10.1002/art.40339

236. Lundberg S, Westergren E, Smolander J, Bruchfeld A. B celldepleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10(1):20-6. doi: 10.1093/ckj/sfw106

237. Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65(1):186-92. doi: 10.1007/s12026-016-8827-5

238. Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schö nlein purpura with rituximab. Scand J Rheumatol. 2016;45(1):83-4. doi: 10.3109/03009742.2015.1058417

239. Pindi Sala T, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent Henoch-Schö nlein purpura adult with rituximab. Case Rep Med. 2014;2014:619218. doi: 10.1155/2014/619218

240. Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schö nlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16(1):71. doi: 10.1186/s12969-018-0285

241. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835-42. doi: 10.1002/art.34322

242. Saadoun D, Rigon MR, Sene D, et al. Rituximab plus PEGinterferon-/ribavirin compared with PEG-interferon-/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116(3):326-34. doi: 10.1182/blood-2009-10-248518

243. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with PEG-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431-6. doi: 10.1136/ard.2007.081653

244. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):843-53. doi: 10.1002/art.34331

245. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup [sic] study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531-40. doi: 10.1002/art.24703

246. Dammacco F, Tucci FA, Lauletta G, et al. PEGylated interferon-, ribavirin, and rituximab combined therapy of hepatitis C virusrelated mixed cryoglobulinemia: a long-term study. Blood. 2010;116(3):343-53. doi: 10.1182/blood-2009-10-245878

247. Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2011;10(11):714-9. doi: 10.1016/j.autrev.2011.04.033

248. Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev. 2015;14(10):889-96. doi: 10.1016/j.autrev.2015.05.013

249. Petrarca A, Rigacci L, Monti M, et al. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Dig Liver Dis. 2007;39(Suppl 1):S129-S133. doi: 10.1016/S1590-8658(07)80025-9

250. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-3. doi: 10.1136/ard.2002.004929

251. Roccatello D, Sciascia S, Rossi D, et al. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Oncotarget. 2017;8(25):41764-77. doi: 10.18632/oncotarget.16986

252. Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken). 2013;65(4):643-7. doi: 10.1002/acr.21856

253. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-39. doi: 10.1056/NEJMra071297

254. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39

255. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):326-37. doi: 10.1038/nrrheum.2010.68

256. Dö rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-58. doi: 10.1016/S0140-6736(19)30546-X

257. Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11(482):eaav1648. doi: 10.1126/scitranslmed.aav1648

258. Durcan L, O'Dwyer T, Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332-43. doi: 10.1016/S0140-6736(19)30237-5

259. Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus – past imperfect, future tense. Nat Rev Rheumatol. 2019;15(7):403-12. doi: 10.1038/s41584-019-0235-5

260. Sanz I. Systemic lupus erythematosus: Extent and patterns of offlabel use of rituximab for SLE. Nat Rev Rheumatol. 2016;12(12):700-2. doi: 10.1038/nrrheum.2016.191

261. Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017;16(6):650-7. doi: 10.1016/j.autrev.2017.04.011

262. Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17(8):781-90. doi: 10.1016/j.autrev.2018.02.011

263. Gordon C, Amissah-Arthur MB, Gayed M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. doi: 10.1093/rheumatology/kex286

264. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic

265. lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089

266. Pons-Estel BA, Bonfa E, Soriano ER, et al. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-57. doi: 10.1136/annrheumdis-2018-213512

267. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-33. doi: 10.1002/art.27233

268. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20:709-16. doi: 10.1177/0961203310395802

269. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359

270. Isenberg DA, Merrill JT. Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016;2:95-8. doi: 10.1586/1744666X.2016.1112270

271. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after Rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118

272. Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology. 2005;44(12):1542-5. doi: 10.1093/rheumatology/kei080

273. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61(4):482-7. doi: 10.1002/art.24341

274. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009

275. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 2013;72(8):1280-6. doi: 10.1136/annrheumdis-2012-202844

276. Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013;22(11):1142-9. doi: 10.1177/0961203313503912

277. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724-31. doi: 10.1136/ard.2007.083162

278. Lindholm C, Borjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826-33.

279. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468-76.

280. Vital EM, Dass S, Buch MH, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011;63(10):3038-47. doi: 10.1002/art.30466

281. Fernandez-Nebro A, de la Fuente JL, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063-76. doi: 10.1177/0961203312446627

282. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541

283. Pinto LF, Velasquez CJ, Prieto C, et al. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus. 2011;20(11):1219-26. doi: 10.1177/0961203311409273

284. Wang CR, Weng CT, Liu MF. Monocentric experience of the rituximab therapy in systemic lupus erythematosus-associated antiphospholipid syndrome with warfarin therapy failure. Semin Arthritis Rheum. 2017;47(1):e7-e8. doi: 10.1016/j.semarthrit.2017.03.012

285. McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. Rheumatology (Oxford). 2018;57(3):470-9. doi: 10.1093/rheumatology/kex395

286. Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2016;4(1):e000182. doi: 10.1136/lupus-2016-000182

287. Chavarot N, Verhelst D, Pardon A, et al; Groupe Cooperatif sur le Lupus Renal. Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore). 2017;96(27):e7429. doi: 10.1097/MD.0000000000007429

288. Aguiar R, Araujo C, Martins-Coelho G, et al. Use of Rituximab in systemic lupus erythematosus: a single Center experience over 14 years. Arthritis Care Res. 2017;69:257-62. doi: 10.1002/acr.22921

289. Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. doi: 10.1177/0961203317749047

290. Torgashina AV, Solovyev SK, Aleksandrova EN, et al. Use of rituximab in patients with lupus nephritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2010;48(4):14-26 (In Russ.). doi: 10.14412/1995-4484-2010-1161

291. Tsanyan ME, Soloviev SK, Radenska-Lopovok SG, et al. Clinical and morphological improvement of lupus nephritis treated with Rituximab. Folia Medica. 2014;56:245. doi: 10.1515/folmed-2015-0003

292. Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology. 2011;50:1640-4. doi: 10.1093/rheumatology/ker176

293. Niaz FA, Aleem A. Response to rituximab in a refractory case of thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Saudi J Kidney Dis Transplant. 2010;21:109.

294. Gupta R, Ezeonyeji A, Thomas A, et al. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus. 2011;20:1547-50. doi: 10.1177/0961203311411349

295. Sardesai VV, Sardesai VR, Agarwal TD. Steroid-resistant autoimmune thrombocytopenia in systemic lupus erythematosus treated with rituximab. Indian J Dermatol. 2015;60:106. doi: 10.4103/0019-5154.147874

296. Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22:664-74. doi: 10.1177/0961203313485489

297. Boyero RG, Esteve EM, Esteve MM, et al. Systemic lupus erythematosus and thrombotic thrombocytopenia purpura: a refractory case without lupus activity. Reumatol Clin. 2013;9:373-5. doi: 10.1016/j.reumae.2012.11.006

298. Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018 Mar;93(3):424-9. doi: 10.1002/ajh.24999

299. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5. doi: 10.1136/ard.2006.057885

300. Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41:364-72. doi: 10.1016/j.semarthrit.2011.06.004

301. Aakjaer S, Bendstrup E, Ivarsen P, Madsen LB. Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome. Respir Med Case Rep. 2017 Sep 30;22:263-5. doi: 10.1016/j.rmcr.2017.09.012

302. Dioszegi A, Tarr T, Nagy-Vincze M, et al. Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. Lupus. 2018 Aug;27(9):1552-8. doi: 10.1177/0961203318768890

303. Bakshi J, Hassan S, D'Cruz D, Chan A. Rituximab therapy in refractory macrophage activation syndrome secondary to systemic lupus erythematosus. Lupus. 2013;22:1544-6. doi: 10.1177/0961203313504634

304. Wang CR, Liu MF, Weng CT, et al. Systemic lupus erythematosus-associated diffuse alveolar haemorrhage: a single-centre experience in Han Chinese patients. Scand J Rheumatol. 2018 Sep;47(5):392-9. doi: 10.1080/03009742.2017.1420817

305. Montes-Rivera G, Rios G, Vila LM. Efficacy of Rituximab in a systemic lupus erythematosus patient presenting with diffuse alveolar hemorrhage. Case Rep Rheumatol. 2017;2017:6031053. doi: 10.1155/2017/6031053

306. Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of response to B-cell depletion using Rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154(12):1432-40. doi: 10.1001/jamadermatol.2018.3793

307. Parodis I, Lopez Benavides AH, Zickert A, et al. The impact of belimumab and rituximab on health-related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23718

308. Peterknecht E, Keasey MP, Beresford MW. The effectiveness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE): A systematic review. Lupus. 2018;27(13):2135-45. doi: 10.1177/0961203318804879

309. Mahmoud I, Jellouli M, Boukhris I, et al. Efficacy and safety of Rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr. 2017;187:213-9.e2. doi: 10.1016/j.jpeds.2017.05.002

310. Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 2017;32(6):1013-21. doi: 10.1007/s00467-017-3583-x

311. Ishaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096

312. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, et al. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in latin american patients with active systemic lupus erythematosus. Autoimmun Rev. 2010;10:108-11. doi: 10.1016/j.autrev.2010.08.012

313. Contis A, Vanquaethem H, Truchetet M-E, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: a chart review. Clin Rheumatol. 2016;35:517-22. doi: 10.1007/s10067-015-3166-9

314. Zhang J, Zhao Z, Hu X. Effect of Rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197-201. doi: 10.1007/s12013-014-0437-z

315. Davies R, Sangle S, Jordan N, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013;22:574-82. doi: 10.1177/0961203313483376

316. Moroni G, Gallelli B, Sinico RA, et al. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. Ann Rheum Dis. 2012;71:1751-2. doi: 10.1136/annrheumdis-2012-201442

317. Turner-Stokes T, Lu TY, Ehrenstein MR, et al. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology. 2011;50:1401-8. doi: 10.1093/rheumatology/ker018

318. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:75. doi: 10.1186/ar3337

319. Andrade-Ortega L, Irazoque-Palazuelos F, Lopez-Villanueva R, et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study. Reumatol Clin. 2010;6:250-5. doi: 10.1016/j.reuma.2009.11.004

320. Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24:2157-60. doi: 10.1093/ndt/gfp002

321. Catapano F, Chaudhry AN, Jones RB, et al. Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586-92. doi: 10.1093/ndt/gfq256

322. Galarza C, Valencia D, Tobon GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol. 2008;34:124-8. doi: 10.1007/s12016-007-8028-z

323. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010;19:213-9. doi: 10.1177/0961203309351541

324. Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913-20. doi: 10.1136/ard.2004.029694

325. Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330-4. doi: 10.1136/ard.2007.079095

326. Lateef A, Lahiri M, Teng G, Vasoo S. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 2010;19:765-70. doi: 10.1177/0961203309358599

327. Reynolds J, Toescu V, Yee C, et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009;18:67-73. doi: 10.1177/0961203308094653

328. Sutter JA, Kwan-Morley J, Dunham J, et al. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol. 2008;126:282-90. doi: 10.1016/j.clim.2007.11.012

329. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17:191-7. doi: 10.3109/s10165-007-0565

330. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:83. doi: 10.1186/ar195

331. Pirone C, Mendoza-Pinto C, van der Windt DA, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review. Semin Arthritis Rheum. 2017 Dec;47(3):384-96. doi: 10.1016/j.semarthrit.2017.04.010

332. Tew GW, Rabbee N, Wolslegel K, et al: Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010;19:146-57. doi: 10.1177/0961203309350752

333. Dias SS, Rodriguez-Garcia V, Nguyen H, et al. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford). 2015;54:1876-81. doi: 10.1093/rheumatology/kev036

334. Jonsdottir T, Gunnarsson I, Mourao AF, et al. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010;49:1502-4. doi: 10.1093/rheumatology/keq055

335. Lazarus MN, Turner-Stokes T, Chavele KM, et al. B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Rheumatology (Oxford). 2012;51:1208-15. doi: 10.1093/rheumatology/ker526

336. Marquez A, Davila-Fajardo CL, Robledo G, et al. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Mol Biol Rep. 2013;40:4851-6. doi: 10.1007/s11033-013-2583-6

337. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66:259-62. doi: 10.1136/ard.2006.067124

338. Robledo G, Davila-Fajardo CL, Marquez A, et al. Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases. DNA Cell Biol. 2012;31:1486-91. doi: 10.1089/dna.2012.1684

339. Robledo G, Marquez A, Davila-Fajardo CL, et al. Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients. DNA Cell Biol. 2012;31:1671-7. doi: 10.1089/dna.2012.1799

340. Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67:1586-91. doi: 10.1002/art.39085

341. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;379(13):1290. doi: 10.1056/NEJMc1

342. Kumar D, Roubey RAS. Use of Rituximab in the antiphospholipid syndrome. Curr Opin Rheumatol. 2010;12:40-4. doi: 10.1007/s11926-009-0074-5

343. Erkan D, Vega J, Ramon G, et al. A pilot open label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464-71. doi: 10.1002/art.37759

344. Sciascia S, Radin M, Cecchi I, et al. Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. Semin Arthritis Rheum. 2018 Apr 11. pii: S0049-0172(18)30097-0. doi: 10.1016/j.semarthrit.2018.04.001

345. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12:1085-90. doi: 10.1016/j.autrev.2013.05.004

346. Rodriguez-Pinto I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015;7(1):26-30. doi: 10.1177/1759720X14554793

347. Dogru A, Ugan Y, Sahin M, et al. Catastrophic antiphospholipid syndrome treated with rituximab: A case report. Eur J Rheumatol. 2017;4(2):145-7. doi: 10.5152/eurjrheum.2017.160073

348. Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome – response to plasmapheresis and rituximab. J Dermatolog Treat. 2017;28(6):564-66. doi: 10.1080/09546634.2017.1282599

349. Sukara G, Baresic M, Sentic M, et al. Catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus treated with rituximab: case report and a review of the literature. Acta Reumatol Port. 2015;40(2):169-75.

350. Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018 Mar;195:76-82. doi: 10.1016/j.imlet.2018.01.002

351. Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20(1):172-3. doi: 10.1038/sj.leu.2403996

352. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578-83. doi: 10.1002/art.24249

353. Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up openlabel trial. Arthritis Res Ther. 2010;12(2):R54. doi: 10.1186/ar2965

354. Daoussis D, Liossis SN, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30(Suppl 71):S17-S22.

355. Smith V, van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193-7. doi: 10.1136/ard.2008.095463

356. Smith V, Piette Y, van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52-7. doi: 10.3899/jrheum.120778

357. Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43(3):257-8. doi: 10.3109/03009742.2013.869617

358. Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our experience

359. and review of the literature. Autoimmun Rev. 2015;14(11):1072-8. doi: 10.1016/j.autrev.2015.07.008

360. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49(2):271-80. doi: 10.1093/rheumatology/kep093

361. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522

362. Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44(4):428-36. doi: 10.1016/j.semarthrit.2014.09.002

363. Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multi-center, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46(5):625-31. doi: 10.1016/j.semarthrit.2016.10.003

364. Thiebaut M, Launay D, Riviere S, et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun Rev. 2018;17(6):582-7. doi: 10.1016/j.autrev.2017.12.010

365. Sari A, Guven D, Armagan B, et al. Rituximab experience in patients with long-standing systemic sclerosis-associated interstitial lung disease: A series of 14 patients. J Clin Rheumatol. 2017 Dec;23(8):411-5. doi: 10.1097/RHU.0000000000000

366. Melsens K, Vandecasteele E, Deschepper E, et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin Belg. 2018 Apr;73(2):119-25. doi: 10.1080/17843286.2017.1

367. Boonstra M, Meijs J, Dorjee AL, et al. Rituximab in early systemic sclerosis. RMD Open. 2017 Jul 28;3(2):e000384. doi: 10.1136/rmdopen-2016-0003

368. Lepri G, Avouac J, Airo P, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):181-5.

369. Vilela VS, Maretti GB, Gama LM, et al. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Rev Bras Reumatol Engl Ed. 2016 Sep-Oct;56(5):458-63. doi: 10.1016/j.rbre.2016.06.003

370. Elhai M, Boubaya M, Distler O, et al; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78(7):979-87. doi: 10.1136/annrheumdis-2018-214816

371. Ananyeva LP, Koneva OA, Desinova OV, et al. Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):265-73 (In Russ.). doi: 10.14412/1995-4484-2019-265-273

372. Koneva OA, Desinova OV, Ananyeva LP, Kovaleva NV. The importance of high-resolution computed tomography in evaluating the efficacy of rituximab in patients with interstitial lung disease in systemic sclerosis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):591-9 (In Russ.). doi: 10.14412/1995-4484-2018-591-599

373. Garzanova LA, Ananyeva LP, Koneva OA, Ovsyannikova OB. Effect of rituximab on heart involvement in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(6):709-15 (In Russ.). doi: 10.14412/1995-4484-2018-709-715

374. Mariette X, Criswell LA. Primary Sjö gren's syndrome. N Engl J Med. 2018 Mar 8;378(10):931-9. doi: 10.1056/NEJMcp170251

375. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541-4. doi: 10.1136/ard.2007.083865

376. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960-96. doi: 10.1002/art.27314

377. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233-42. doi: 10.7326/M13-1085

378. Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15(5):R172. doi: 10.1186/ar4359

379. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, et al. Brief report: ultrasonographic assessment of salivary gland response to rituximab in primary Sjogren's syndrome. Arthritis Rheum. 2015;67(6):1623-8. doi: 10.1002/art.39088

380. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293

381. Meiners PM, Arends S, Meijer JM, et al. Efficacy of retreatment with rituximab in patients with primary Sjogren's syndrome. Clin Exp Rheumatol. 2015;33(3):443-4.

382. Cornec D, Costa S, Devauchelle-Pensec V, et al. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjogren's syndrome. J Autoimmun. 2016;67:102-10. doi: 10.1016/j.jaut.2015.11.002

383. Delli K, Haacke EA, Kroese FG, et al. Towards personalized treatment in primary Sjogren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016;75(11):1933-8. doi: 10.1136/annrheumdis-2015-208304

384. Bowman SJ, Everett CC, O'Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjö gren's syndrome. Arthritis Rheum. 2017;69(7):1440-50. doi: 10.1002/art.40093

385. Fisher BA, Everett CC, Rout J, et al. Effect of rituximab on a salivary gland ultrasound score in primary Sjö gren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 2018;77(3):412-6. doi: 10.1136/annrheumdis-2017-212268

386. Souza FB, Porfirio GJ, Andriolo BN, et al. Rituximab effectiveness and safety for treating primary Sjogren's syndrome (pSS): systematic review and meta-analysis. PLoS One. 2016;11(3):e0150749. doi: 10.1371/journal.pone.0150749

387. Fox RI, Fox CM. Sjogren syndrome: why do clinical trials fail? Rheum Dis Clin North Am. 2016;42(3):519-30. doi: 10.1016/j.rdc.2016.03.009

388. Letaief H, Lukas C, Barnetche T, et al. Efficacy and safety of biological DMARDs modulating B cells in primary Sjö gren's syndrome: Systematic review and meta-analysis. Joint Bone Spine. 2018 Jan;85(1):15-22. doi: 10.1016/j.jbspin.2017.06.004

389. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 2014;73:472-4. doi: 10.1136/annrheumdis-2013-203736

390. Moerman RV, Arends S, Meiners PM, et al. Detailed analysis of the articular domain in patients with primary Sjö gren syndrome. J Rheumatol. 2017;44:292-6. doi: 10.3899/jrheum.160459

391. Carsons SE, Vivino FB, Parke A, et al.Treatment guidelines for rheumatologic manifestations of Sjö gren's syndrome: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res. 2017;69:517-27. doi: 10.1002/acr.22968

392. Verstappen GM, van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjö gren's syndrome. Clin Immunol. 2017;182:62-71. doi: 10.1016/j.clim.2017.05.002

393. Chen MH, Chen CK, Chou HP, et al. Rituximab therapy in primary Sjogren's syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol. 2016;34(6):1077-84.

394. Mekinian A, Ravaud P, Larroche C, et al; Club Rhumatismes et Inflammation. Rituximab in central nervous system manifestations of patients with primary Sjö gren's syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208-12.

395. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84-7. doi: 10.1136/annrheumdis-2011-200086

396. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjö gren's syndrome. Ann Rheum Dis. 2007;66:351-7. doi: 10.1136/ard.2006.057919

397. Мeiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297-302. doi: 10.1136/annrheumdis-2011-200460

398. Nocturne G, Virone A, Ng W-F, et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjö gren's syndrome. Arthritis Rheum. 2016;68:977-85. doi: 10.1002/art.39518

399. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjö gren's syndrome after two infusions of rituximab (antiCD20). Arthritis Rheum. 2007;57:310-7. doi: 10.1002/art.22536

400. Clair EW St, Levesque MC, Prak ETL, et al. Autoimmunity centers of excellence, rituximab therapy for primary Sjö gren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097-106. doi: 10.1002/art.37850

401. Verstappen GM, Kroese FGM, Meiners PM, et al. B cell depletion therapy normalizes circulating follicular Th cells in primary Sjogren syndrome. J Rheumatol. 2017;44:49-58. doi: 10.3899/jrheum.160313

402. Lindop R, Arentz G, Bastian I, et al. Long-term Ro60 humoral autoimmunity in primary Sjö gren's syndrome is maintained by rapid clonal turnover. Clin Immunol. 2013;148:27-34. doi: 10.1016/j.clim.2013.03.015

403. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8:e59868. doi: 10.1371/journal.pone.0059868

404. Pollard RP, Abdulahad WH, Bootsma H, et al. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome. Ann Rheum Dis. 2013;72:2048-50. doi: 10.1136/annrheumdis-2013-203447

405. Dalakas MC. Inflammatory Muscle Diseases. N Engl J Med. 2015;373(4):393-404. doi: 10.1056/NEJMc1506827

406. Ghirardello A, Borella E, Beggio M, et al. Myositis autoantibodies and clinical phenotypes. Auto Immun Highlights. 2014;5(3):69-75. doi: 10.1007/s13317-014-0060-4

407. Barsotti S, Cioffi E, Tripoli A, et al. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature. Reumatismo. 2018 Jul 6;70(2):78-84. doi: 10.4081/reumatismo.2

408. Fasano S, Gordon P, Hajji R, et al. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford). 2017 Jan;56(1):26-36. doi: 10.1093/rheumatology/kew146

409. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7. doi: 10.1002/art.20849

410. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763-7. doi: 10.1001/archderm.143.6.763

411. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-71. doi: 10.1093/rheumatology/kep157

412. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328-34. doi: 10.1002/acr.20219

413. Mahler EAM, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50:2206-13. doi: 10.1093/rheumatology/ker088

414. Couderc M, Gottenberg J-E, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology. 2011;50:2283-9. doi: 10.1093/rheumatology/ker305

415. Marie I, Dominique S, Janvresse A, et al. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106:581-7. doi: 10.1016/j.rmed.2012.01.001

416. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-24. doi: 10.1002/art.37754

417. Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017 Feb;56(2):247-54. doi: 10.1093/rheumatology/kew396

418. Unger L, Kampf S, Lü thke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology. 2014;53:1630-8. doi: 10.1093/rheumatology/keu024

419. Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology. 2015;54:1420-8. doi: 10.1093/rheumatology/kev004

420. Rider LG, Yip AL, Horkayne-Szakaly I, et al. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol. 2014;32:689-96.

421. Keir GJ, Maher TM, Ming D, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353-9. doi: 10.1111/resp.12214

422. Allenbach Y, Guiguet M, Rigolet A, et al. Efficacy of Rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: An open-label, phase ii trial. PLoS One. 2015 Nov 5;10(11):e0133702. doi: 10.1371/journal.pone.0133

423. Doyle TJ, Dhillon N, Madan R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: A multicenter retrospective case review. J Rheumatol. 2018 Jun;45(6):841-50. doi: 10.3899/jrheum.170541

424. Khelkovskaya-Sergeeva AN, Antelava OA, Olunin YA, Tarasova GM, Lopatina NE, Palshina SE, Sazhina EG, Nasonov EL. Rituximab in patients with idiopathic inflammatory myopathies associated with interstitial lung disease. Ann Rheum Dis. 2016;75:741-2 [SAT0203].

425. Bauhammer J, Blank N, Max R, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016 Aug;43(8):1566-74. doi: 10.3899/jrheum.15

426. Lambotte O, Kotb R, Maigne G, et al. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32:1369-70.

427. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264-6. doi: 10.1097/01.rhu.0000182155.08982.60

428. Brulhart L,Waldburger J-M, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65:974-5. doi: 10.1136/ard.2005.045898

429. Zappa MC, Trequattrini T, Mattioli F et al. Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med. 2011;6:183-8. doi: 10.1186/2049-6958-6-3-183

430. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56:148-53. doi: 10.1016/j.jaad.2006.05.068

431. Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38:1436-40. doi: 10.3899/jrheum.101321

432. Rios Fernandez R, Callejas Rubio J-L, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27:1009-16.

433. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum. 2014;66:740-9. doi: 10.1002/art.38270

434. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9):1181-92. doi: 10.1038/modpathol.2012.72

435. Sedyshev SK, Vasiliev VI, Kovriguina AM, Nasonov EL. IgG4-linked systemic disease. Modern outlook on «old» disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):64-72 (In Russ.). doi: 10.14412/1995-4484-2012-1184

436. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51. doi: 10.1056/NEJMra1104650

437. Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460-71. doi: 10.1016/S0140-6736(14)60720-0

438. Сокол ЕВ, Васильев ВИ. Лечение IgG4-связанного заболевания. Научно-практическая ревматология. 2016;54(3):352-60 [Sokol EV, Vasilyev VI. Treatment of IgGrelated disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):352-60 (In Russ.)]. doi: 10.14412/1995-4484-2016-352-360

439. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2

440. Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19(5):536-42. doi: 10.1007/s00534-012-0521-y

441. Brito-Zeron P, Kostov B, Bosch X, et al. Therapeutic approach to IgG4-related disease: A systematic review. Medicine (Baltimore). 2016;95(26):e4002. doi: 10.1097/MD.0000000000004002

442. Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015;181(2):191-206. doi: 10.1111/cei.12641

443. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020

444. Vasil'ev VI, Pal'shina SG, Simonova MV, et al. The first experience with rituximab in the treatment of Mikulich’s diseases. Terapevticheskiy Arkhiv. 2010;82(6):62-6 (In Russ.).

445. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010;62(6):1755-62. doi: 10.1002/art.27435

446. Sedyshev SKh, Vasil'ev V.I. Kovrigina FM, et al. IgG4-related disease: characterization of the patient group and rituximab therapy. Terapevticheskiy Arkhiv. 2013;85(2):48-53 (In Russ.).

447. McMahon BA, Novick T, Scheel PJ, et al. Rituximab for the Treatment of IgG4-Related Tubulointerstitial Nephritis: Case Report and Review of the Literature. Medicine (Baltimore). 2015;94(32):e1366. doi: 10.1097/MD.0000000000001366

448. Zaidan M, Cervera-Pierot P, de Seigneux S, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. Nephrol Dial Transplant. 2011;26(6):2047-50. doi: 10.1093/ndt/gfr097

449. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57-66. doi: 10.1097/MD.0b013e3182431ef6

450. Wallace ZS, Mattoo H, Mahajan VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016;55(6):1000. doi: 10.1093/rheumatology/kev438

451. Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015;29(1):122. doi: 10.1038/eye.2014.251

452. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis. 2015;74(8):e46 doi: 10.1136/annrheumdis-2015-207625

453. Pomponio G, Olivari D, Mattioli M, et al. Sustained clinical response after single course of rituximab as first-line monotherapy in adult-onset asthma and periocular xanthogranulomas syndrome associated with IgG4-related disease: A case report. Medicine (Baltimore). 2018 Jun;97(26):e11143. doi: 10.1097/MD.00000000000

454. Quattrocchio G, Barreca A, Demarchi A, et al. IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. Oncotarget. 2018 Apr 20;9(30):21337-47. doi: 10.18632/oncotarget.25095

455. Gu WJ, Zhang Q, Zhu J, et al. Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore). 2017 Jun;96(24):e6934. doi: 10.1097/MD.0000000000006

456. Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One. 2017 Sep 15;12(9):e0183844. doi: 10.1371/journal.pone.0183844

457. Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. Longterm efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1947-53. doi: 10.1016/j.cgh.2018.0

458. Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605

459. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol. 2017;13(4):217-33. doi: 10.1038/nrrheum.2017.22

460. Nasonov EL, Reshetnyak TM, Denisov LN, et al. Belimumab: advances in drug therapy for systemic lupus erythematosus. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):13-9 (In Russ.). doi: 10.14412/1995-4484-2012-1174

461. Samy E, Wax S, Huard B, et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36(1):3-19. doi: 10.1080/08830185.2016.1276903

462. Ehrenstein MR,Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-72. doi: 10.1038/nrrheum.2016.18

463. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328-37. doi: 10.1002/art.34400

464. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of shortterm anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010;62:2443-57. doi: 10.1002/art.27515

465. Lin W, Seshasayee D, Lee WP, et al. Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus. Arthritis Rheum. 2015;67:215-24. doi: 10.1002/art.38907

466. Carter LM, Isenberg DA. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2672-9. doi: 10.1002/art.38074

467. Kraaij T, Huizinga TW, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53:2122-4. doi: 10.1093/rheumatology/keu369

468. Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235-6. doi: 10.1016/j.jbspin.2016.01.008

469. Gonzalez-Echavarri C, Ugarte A, Ruiz-Irastorza G. Rituximabrefractory lupus nephritis successfully treated with belimumab. Clin Exp Rheumatol. 2016;34:355-56.

470. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjö gren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol. 2014;32:490-4.

471. Gualtierotti R, Borghi MO, Gerosa M, et al. Successful sequential therapy with rituximab and belimumab in patients with active systemiclupus erythematosus: a case series. Clin Exp Rheumatol. 2018 Feb 27.

472. Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003

473. Aranow C, Dall'Era M, Byron M, et al., on behalf of the CALIBRATE investigators and Lupus Phase 2 trial of induction therapy with anti-CD20 (rituximab) followed by maintenance therapy with anti-BAFF (belimumab) in patients with active lupus nephritis [abstract]. Ann Rheum Dis. 2018;77:A690. doi: 10.1136/annrheumdis-2018-eular.5711

474. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis. 2015;74(3):526-31. doi: 10.1136/annrheumdis-2013-203991

475. Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275.

476. doi: 10.1186/s13063-017-2016-2

477. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03312907

478. BEAT Lupus. https://beatlupus.uk/ (2017).

479. ClinicalTrials.gov. NCT03054259

480. ClinicalTrials.gov. number NCT01773616

481. ClinicalTrials.gov. Identifier: NCT01748084

482. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02631538

483. ClinicalTrials.gov. Identifier: NCT02990286

484. Mesnyankina AA, Solovyev SK, Aleksandrova EN, et al. Dual therapy with biologicals in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):281-8 (In Russ.). doi: 10.14412/1995-4484-2016-281-288

485. Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309

486. Beketova TV, Volkov MYu, Nikonorova NO, Novoselova TM. Experience with effective combined anti-Bcell therapy with rituximab and belimumab for refractory granulomatosis with polyangiitis (Wegener's) with severe lung damage. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):104-9 (In Russ.). doi: 10.14412/1995-4484-2017-104-109

487. Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60-5. doi: 10.1016/j.jaut.2014.11.009

488. Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2:594-600. doi: 10.1016/j.jaip.2014.06.003

489. Kobelt G, Kasteng F. Access to Innovative Treatments in Rheumatoid Arthritis in Europe. 2009. Available at: http://www.comparatorreports.se/Access to MS treatments - October 2009.pdf

490. Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279

491. Dö rner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974-82. doi: 10.1136/annrheumdis-2016-209166

492. Kay J, Schoels MM, Dö rner T, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165-74. doi: 10.1136/annrheumdis-2017-211937

493. Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019 May 21;5(1):e000900. doi: 10.1136/rmdopen-2019-000900

494. Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.). doi: 10.14412/1995-4484-2016-628-640

495. Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: Rituximab. Arthritis. 2018;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018.

496. Yoo DH, Suh CH, Shim SC, et al. A multicentre randomized controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76:566-70. doi: 10.1136/annrheumdis-2016-209540

497. Park W, Bozic-Majstorovic L, Milakovic D, et al. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial. MAbs. 2018;10(6):934-43. doi: 10.1080/19420862.2018.1487912

498. Cohen SB, Burgos-Vargas R, Emery P, et al. An extension study of PF-05280586, a potential Rituximab biosimilar, versus Rituximab in subjects with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2018 Apr 25. doi: 10.1002/acr.23586

499. Nasonov EL, Mazurov VI, Usacheva YuV, et al. Developments of Russian original biological agents for the treatment of immunoinflammatory rheumatic diseases. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):201-10 (In Russ.). doi: 10.14412/1995-4484-2017-201-210

500. Nasonov EL, Zonova EV, Ivanova ON, et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and MabThera®) in rheumatoid arthritis (the BIORA study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):510-9 (In Russ.). doi: 10.14412/1995-4484-2016-510-519

501. Nasonov EL, Mazurov VI, Zonova EV, et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: Results of Phase III (ALTERRA) clinical trial. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):351-9 (In Russ.). doi: 10.14412/1995-4484-2017-351-359

502. Bredemeier M, de Oliveira FK, Rocha CM. Low-versus Highdose rituximab for rheumatoid arthritis: a systemic review and meta-analysis. Arthritis Care Res. 2014;66:228-35. doi: 10.1002/acr.22116

503. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-20. doi: 10.1136/ard.2010.144998

504. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400. doi: 10.1002/art.21778

505. Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab. Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. J Rheumatol. 2008;35:20-30.

506. Mease P, Szechinski J, Greenwald M, et al. Improvements in patient reported outcomes over 24 weeks for rituximab with methotrexate in rheumatoid arthritis patients in phase IIb trial (DANCER) [abstract]. Arthritis Rheum. 2005;52 Suppl:S138-9.

507. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX inadequate responders (SERENE)). Ann Rheum Dis. 2010;69:1629-35. doi: 10.1136/ard.2009.119933

508. Deodhar A, Isaacs J, Rigby W, et al. Improved quality of life (QoL) with rituximab (RTX) as first-line biologic therapy in patients (pts) with active rheumatoid arthritis (RA): results from a phase III randomized controlled study (SERENE) [abstract]. Arthritis Rheum. 2008;58 Suppl:S302.

509. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint dam- age and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70:39-46. doi: 10.1136/ard.2010.137703

510. Tak PP, Rigby W, Rubbert A, et al. Rituximab plus methotrexate (MTX) inhibits joint damage and improves clinical outcomes in patients with early, active rheumatoid arthritis (RA) who are naive to MTX [abstract]. Rheumatology (Oxford). 2010;49:i4.

511. Rigby W, Ferraccioli G, Greenwald M, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res (Hoboken). 2011;63:711-20. doi: 10.1002/acr.20419

512. Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71:351-7. doi: 10.1136/annrheumdis-2011-200170

513. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49:1683-93. doi: 10.1093/rheumatology/keq116

514. Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis. 2016;75(1):170-7. doi: 10.1136/annrheumdis-2014-206015

515. Welsing PM, Borm GF, van Riel P. Minimal clinically important difference in radiological progression of joint damage: a definition based on patient perspective. J Rheumatol. 2006;33:501-7.

516. Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21. doi: 10.1093/rheumatology/kep155

517. Mariette X, Rouanet S, Sibilia J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480

518. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016;18:50. doi: 10.1186/s13075-016-0951-z

519. Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-8. doi: 10.1002/art.30152

520. McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford). 2008;47:865-7. doi: 10.1093/rheumatology/ken103

521. Reddy V, Leandro M. Variability in clinical and biological response to rituximab in autoimmune disease: an opportunity for personalized therapy? Int J Clin Rheumatol. 2014;9(3):279-93. doi: 10.2217/ijr.14.18

522. Tesfa D, Ajeganova S, Hagglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63:2209-14. doi: 10.1002/art.30427

523. Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-сenter study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012;79:365-9. doi: 10.1016/j.jbspin.2011.12.004

524. Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venerol. 2017;83(3):317-25. doi: 10.4103/ijdvl.IJDVL_1078_14

525. Robinson AJ, Vu M, Unglik GA, et al. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and singlecentre long-term review of nine patients. Australas J Dermatol. 2017 Feb 17. doi: 10.1111/ajd.12571

526. Moroni G, Depetri F, Del Vecchio L, et al. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transplant. 2016 Jul 6. doi: 10.1093/ndt/gfw251

527. Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546-51. doi: 10.1111/ejh.12199

528. Gomez-Almaguer D, Tarin-Arzaga L, Moreno-Jaime B, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494-500. doi: 10.1111/ejh.12102

529. Hua Chen, Wenjie Zheng, Jinmei Su, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus – a prospective pilot study. Rheumatology (Oxford). 2011;50(9):1640-4. doi: 10.1093/rheumatology/ker176

530. Van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5 year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-502. doi: 10.1136/annrheumdis-2012-201956

531. Keystone E, Fleishmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896-908. doi: 10.1002/art.23059

532. Thurlings RM, Teng O, Vos K, et al. Clinical response, pharmacokinetics, development of human anti-chimeric antibodies and synovial tissue response to rituximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;69(2):409-12. doi: 10.1136/ard.2009.109041

533. Avdeeva AS, Satybaldyev AM, Demidova NV, et al. Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis). NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(3):274-9 (In Russ.). doi: 10.14412/1995-4484-2019-274-279

534. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484

535. Bae SC, Lee YH. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis. Int J Clin Pharmacol Ther. 2019 57(4):188-96. doi: 10.5414/CP203360

536. Tony HP, Krü ger K, Cohen SB, et al. Brief report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference Rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71(1):88-94. doi: 10.1002/acr.23771

537. Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases-evidence based analysis. Autoimmun Rev. 2019;18(1):93-106. doi: 10.1016/j.autrev.2018.08.003

538. Jog NR, James J. Biomarkers in connective tissue diseases. A. J Allergy Clin Immunol. 2017;140(6):1473-83. doi: 10.1016/j.jaci.2017.10.003

539. Aleksandrova EN, Novikov AA, Nasonov EL. Current approaches to the laboratory diagnosis of rheumatic diseases: Role of molecular and cellular biomarkers. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):324-38 (In Russ.). doi: 10.14412/1995-4484-2016-324-338

540. Avdeeva AS, Artyukhov AS, Dashinimaeva EB, et al. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):46-55 (In Russ.). doi: 10.14412/1995-4484-2019-46-55

541. Avdeeva AS, Cherkasova MV, Kusevich DA, et al. Immunological effects of a rituximab biosimilar (Acelbia, BIOCAD) in patients with rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(5):556-63 (In Russ.). doi: 10.14412/1995-4484-2018-556-563

542. Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8:515-9. doi: 10.1016/j.autrev.2009.01.007

543. Grosjean C, de Chaisemartin L, Nicaise-Roland P, et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis. 2008;67(Suppl II):196.

544. Aleksandrova EN, Avdeyeva AS, Lukina GV, et al. The clinical and immunological effects of anti-B-cell therapy in patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):14-21 (In Russ.). doi: 10.14412/1995-4484-2012-498

545. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723-32. doi: 10.1002/art.21650

546. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-806. doi: 10.1002/art.22025

547. Higashida J, Wun T, Schmidt S. Safety and efficacy of Rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-a treatment. Rheumatology. 2005;32:2109-15.

548. Tsiakalos A, Avgoustidis N, Moutsopoulos H. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics: Targets Ther. 2008;2:911-6. doi: 10.2147/BTT.S3939

549. Bokareva M, Lindholm C, Zendjanchi K, et al. Efficacy of antiCD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol. 2007;66:467-83. doi: 10.1111/j.1365-3083.2007.01995.x

550. Toubi E, Kesser A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20. doi: 10.1136/ard.2006.062505

551. Vizioli C, Viana V, Ribeiro A. Auto-antibody titers for monitoring rituximab therapy in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:667. doi: 10.1136/annrheumdis-2012-eular.519

552. Aletaha D, Blü ml S. Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. 2016;2:e000009. doi: 10.1136/rmdopen-2014-000009

553. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford). 2012;51(4):634-43. doi: 10.1093/rheumatology/ker150

554. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133

555. Price EJ, Rauz S, Tappuni AR, et al. The British Society for Rheumatology guideline for the management of adults with primary Sjö gren's Syndrome. Rheumatology (Oxford). 2017 1;56(10):e24-e48. doi: 10.1093/rheumatology/kex166

556. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018;17(9):816-28. doi: 10.1016/S1474-4422(18)30254-0

557. Clinical Commissioning Policy: Rituximab for the treatment of dermatomyositis and polymyositis. NHS England 16036/P, 2017.

558. Fernandez-Codina A, Walker KM, Pope JE, on behalf of the Scleroderma Algoritm Group. Treatment Algoritm for Systemic Sclerosis According to Expert. Arthritis Rheum. 2018;70:1820-8. doi: 10.1002/art.40560